NEW YORK, New York and CAMBRIDGE, Massachusetts, August 1, 2023 – The National Urban League, a historic civil rights and urban advocacy organization, and Takeda (TSE:4502/NYSE:TAK) together announce a new health equity initiative that seeks to address the obstacles that disproportionately hinder access to better health care for historically marginalized populations in the U.S.
This partnership will ultimately help to raise awareness, knowledge and action across the National Urban League’s network of local affiliates and partners on social determinants of health (SDOH) and the barriers to accessing timely diagnosis and treatment in communities. Takeda’s support through this initiative will enable the creation of a Health Equity Continuum of Service Structure across the National Urban League’s network, including the development and implementation of local health equity plans to address identified health inequities and barriers to access in communities. Additionally, Takeda will support the National Urban League in developing webinars and workshops for continued health equity education and professional development among its affiliates. Long-term efforts under this partnership will engage key stakeholders to shape local and national policy, institutional commitments and structural investments in communities to achieve health equity holistically.
"The COVID-19 pandemic shone a harsh light on the historic and structural inequities in our health care system and the urgent need for reform," said Marc H. Morial, president and CEO of the National Urban League. "The National Urban League is proud to work with forward-thinking partners like Takeda, the first organization to fund our health equity infrastructure."
“Working alongside trusted leaders in the community and community-based organizations is vital to ensure we’re prioritizing the complex needs of historically marginalized people and can help to implement thoughtful solutions,” said Dr. Chris Reddick, head of U.S. Health Equity at Takeda. “That’s why we’ve partnered with the National Urban League, an organization that looks to the root of inequities and prioritizes community-led solutions to deliver care that reflects local needs.”
Health inequities result in higher rates of disease and poorer health outcomes for a wide range of health conditions among people in racial and ethnic groups when compared to their white counterparts.1 For example, the average life expectancy among Black or African American people in the U.S. is four years lower than that of white people.2 Data also shows that LGBTQ+ people were more likely than their non-LGBTQ+ counterparts to report negative experiences while receiving health care.1 In order to solve for these deep-rooted health disparities, Takeda is committed to supporting community-serving organizations that are closest to the nuanced challenges and needs of a population, to ultimately create lasting change.
The National Urban League is a historic civil rights and organization dedicated to economic empowerment in order to elevate the standard of living in historically underserved urban communities. The National Urban League spearheads the efforts of its 90 local affiliates through the development of programs, public policy research and advocacy, providing direct services that impact and improve the lives of more than three million people annually nationwide. Visit www.nul.org and follow us on Facebook, Twitter and Instagram: @NatUrbanLeague.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.